PCM
CGEM icon

Prelude Capital Management’s Cullinan Oncology CGEM Stock Holding History

Prelude Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,652
Closed -$289K – 1324
2025
Q3 		$289K Buy
48,652
+32,500
+201% +$238K 0.02% 750
2025
Q2 		$122K Buy
16,152
+6,000
+59% +$48.2K 0.01% 883
2025
Q1 		$76.9K Buy
+10,152
New +$97.4K 0.01% 1063
2024
Q1 		– Sell
-17,844
Closed -$182K – 1337
2023
Q4 		$182K Buy
17,844
+5,300
+42% +$47K 0.01% 963
2023
Q3 		$114K Buy
+12,544
New +$131K 0.01% 977
2023
Q2 		– Sell
-11,044
Closed -$113K – 1154
2023
Q1 		$113K Sell
11,044
-500
-4% -$5.51K 0.01% 940
2022
Q4 		$122K Buy
+11,544
New +$140K 0.01% 1042

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Prelude Capital Management's CGEM Position: Q4 2025 in Review

Prelude Capital Management sold out of Cullinan Oncology (CGEM) in Q4 2025, closing a stake of 48,652 shares — an estimated $289K sold.

Prelude Capital Management first reported a position in CGEM in Q4 2022 and held it in 7 quarters. The position peaked at $289K in Q3 2025. 153 funds tracked by Wall St. Rank hold CGEM as of Q4 2025.

  • Prelude Capital Management reported no remaining Cullinan Oncology position as of Q4 2025 after selling out during the quarter.
  • Prelude Capital Management sold 48,652 Cullinan Oncology shares in Q4 2025, an estimated $289K.
  • Prelude Capital Management first reported a position in Cullinan Oncology in Q4 2022 and held it in 7 quarters.
  • Prelude Capital Management's Cullinan Oncology position peaked at $289K in Q3 2025.
  • 153 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.